Getein Biotech, Inc (SHA:603387)
China
· Delayed Price · Currency is CNY 8.44
+0.04 (0.48%)
Mar 10, 2026, 2:14 PM CST
Getein Biotech Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | Current | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 9, 2026 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Market Capitalization | 4,260 | 4,184 | 5,579 | 6,339 | 7,254 | 8,911 | Upgrade
|
| Market Cap Growth | 0.24% | -25.00% | -12.00% | -12.61% | -18.60% | 48.48% | Upgrade
|
| Enterprise Value | 3,861 | 3,896 | 5,572 | 5,454 | 6,496 | 8,162 | Upgrade
|
| Last Close Price | 8.40 | 8.07 | 10.50 | 11.56 | 13.02 | 15.69 | Upgrade
|
| PE Ratio | 20.47 | 18.71 | 19.94 | 12.71 | 18.18 | 29.24 | Upgrade
|
| Forward PE | - | 17.43 | 17.43 | 17.43 | 17.43 | 17.55 | Upgrade
|
| PS Ratio | 4.09 | 3.59 | 4.08 | 3.48 | 5.18 | 7.93 | Upgrade
|
| PB Ratio | 1.52 | 1.54 | 2.04 | 2.38 | 3.19 | 4.45 | Upgrade
|
| P/TBV Ratio | 1.68 | 1.69 | 2.31 | 2.70 | 3.62 | 5.10 | Upgrade
|
| P/FCF Ratio | 22.95 | 15.69 | 74.29 | 23.88 | 28.70 | 123.88 | Upgrade
|
| P/OCF Ratio | 10.43 | 9.89 | 16.74 | 13.13 | 16.78 | 48.05 | Upgrade
|
| EV/Sales Ratio | 3.70 | 3.34 | 4.07 | 2.99 | 4.64 | 7.27 | Upgrade
|
| EV/EBITDA Ratio | 16.92 | 12.71 | 18.72 | 9.71 | 14.21 | 23.77 | Upgrade
|
| EV/EBIT Ratio | 28.47 | 17.65 | 26.25 | 10.97 | 15.86 | 26.55 | Upgrade
|
| EV/FCF Ratio | 20.80 | 14.61 | 74.20 | 20.54 | 25.70 | 113.47 | Upgrade
|
| Debt / Equity Ratio | 0.23 | 0.21 | 0.24 | 0.22 | 0.22 | 0.19 | Upgrade
|
| Debt / EBITDA Ratio | 2.77 | 1.86 | 2.18 | 1.04 | 1.08 | 1.12 | Upgrade
|
| Debt / FCF Ratio | 3.40 | 2.18 | 8.88 | 2.23 | 1.96 | 5.35 | Upgrade
|
| Net Debt / Equity Ratio | -0.18 | -0.15 | -0.10 | -0.21 | -0.48 | -0.50 | Upgrade
|
| Net Debt / EBITDA Ratio | -2.29 | -1.37 | -0.90 | -1.01 | -2.37 | -2.95 | Upgrade
|
| Net Debt / FCF Ratio | -2.74 | -1.57 | -3.59 | -2.13 | -4.29 | -14.06 | Upgrade
|
| Asset Turnover | 0.27 | 0.31 | 0.37 | 0.54 | 0.48 | 0.48 | Upgrade
|
| Inventory Turnover | 1.69 | 1.77 | 1.92 | 2.58 | 2.09 | 2.22 | Upgrade
|
| Quick Ratio | 1.58 | 1.50 | 1.56 | 1.77 | 2.54 | 2.86 | Upgrade
|
| Current Ratio | 2.32 | 1.98 | 2.20 | 2.50 | 2.91 | 3.22 | Upgrade
|
| Return on Equity (ROE) | 7.12% | 8.42% | 10.51% | 20.41% | 19.26% | 17.92% | Upgrade
|
| Return on Assets (ROA) | 2.18% | 3.69% | 3.56% | 9.11% | 8.77% | 8.16% | Upgrade
|
| Return on Invested Capital (ROIC) | 5.42% | 8.39% | 8.65% | 27.21% | 34.26% | 33.27% | Upgrade
|
| Return on Capital Employed (ROCE) | 4.80% | 8.00% | 7.60% | 18.30% | 17.60% | 15.00% | Upgrade
|
| Earnings Yield | 4.90% | 5.34% | 5.01% | 7.87% | 5.50% | 3.42% | Upgrade
|
| FCF Yield | 4.36% | 6.37% | 1.35% | 4.19% | 3.48% | 0.81% | Upgrade
|
| Dividend Yield | 2.15% | 2.23% | 1.91% | 2.94% | 1.86% | 1.17% | Upgrade
|
| Payout Ratio | 49.49% | 49.63% | 78.42% | 28.21% | 25.96% | 38.01% | Upgrade
|
| Buyback Yield / Dilution | -1.16% | 0.08% | 0.08% | 0.48% | -0.72% | 0.82% | Upgrade
|
| Total Shareholder Return | 0.98% | 2.31% | 1.99% | 3.42% | 1.15% | 1.99% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.